These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 30813769)

  • 21. Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON).
    Göbel H; Schlegel E; Jaeger K; Ortler S; Leist L
    J Headache Pain; 2024 Sep; 25(1):157. PubMed ID: 39322961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
    Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab).
    Garces F; Mohr C; Zhang L; Huang CS; Chen Q; King C; Xu C; Wang Z
    Cell Rep; 2020 Feb; 30(6):1714-1723.e6. PubMed ID: 32049005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.
    Lattanzi S; Brigo F; Trinka E; Vernieri F; Corradetti T; Dobran M; Silvestrini M
    Drugs; 2019 Mar; 79(4):417-431. PubMed ID: 30793254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
    Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
    JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.
    Urits I; Jones MR; Gress K; Charipova K; Fiocchi J; Kaye AD; Viswanath O
    Curr Pain Headache Rep; 2019 Mar; 23(5):29. PubMed ID: 30874961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erenumab efficacy in migraine headache prophylaxis: A systematic review.
    Bagherzadeh-Fard M; Amin Yazdanifar M; Sadeghalvad M; Rezaei N
    Int Immunopharmacol; 2023 Apr; 117():109366. PubMed ID: 37012858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timing and durability of response to erenumab in patients with episodic migraine.
    McAllister PJ; Turner I; Reuter U; Wang A; Scanlon J; Klatt J; Chou DE; Paiva da Silva Lima G
    Headache; 2021 Nov; 61(10):1553-1561. PubMed ID: 34841526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
    J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
    Arca K; Reynolds J; Sands KA; Shiue HJ
    Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
    [No Abstract]   [Full Text] [Related]  

  • 31. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
    Tepper SJ; Diener HC; Ashina M; Brandes JL; Friedman DI; Reuter U; Cheng S; Nilsen J; Leonardi DK; Lenz RA; Mikol DD
    Neurology; 2019 May; 92(20):e2309-e2320. PubMed ID: 30996056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
    Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Hines DM; Shah S; Multani JK; Wade RL; Buse DC; Bensink M
    Headache; 2021 Apr; 61(4):590-602. PubMed ID: 33594672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.
    Ornello R; Casalena A; Frattale I; Gabriele A; Affaitati G; Giamberardino MA; Assetta M; Maddestra M; Marzoli F; Viola S; Cerone D; Marini C; Pistoia F; Sacco S
    J Headache Pain; 2020 Apr; 21(1):32. PubMed ID: 32264820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries.
    Ohlsson L; Haanes KA; Kronvall E; Xu C; Snellman J; Edvinsson L
    Cephalalgia; 2019 Dec; 39(14):1745-1752. PubMed ID: 31366221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
    Tepper SJ; Lipton RB; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Wang A; Cheng S; Klatt J; Mikol DD
    Headache; 2023 Jun; 63(6):730-742. PubMed ID: 37313616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.
    de Hoon J; Van Hecken A; Vandermeulen C; Yan L; Smith B; Chen JS; Bautista E; Hamilton L; Waksman J; Vu T; Vargas G
    Clin Pharmacol Ther; 2018 May; 103(5):815-825. PubMed ID: 28736918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.